|
|
||||||||




Section of Transplantation, Departments of
*
Surgery and
Pathology, and
Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637
STAT4-/- mice have impaired type 1 T cell
differentiation, whereas STAT6-/- mice fail to generate
type 2 responses. The role of type 1 and type 2 T cell differentiation
in acute cardiac allograft rejection and in the induction of tolerance
was examined in wild-type, STAT4-/-, and
STAT6-/- recipients. All recipients rejected the grafts
promptly. Analysis of in situ cytokine gene expression in the
allografts confirmed decreased levels of IFN-
in
STAT4-/- recipients and undetectable levels of IL-4 and
IL-5 in STAT6-/- mice. Blockade of the CD28/B7
costimulatory pathway prolonged cardiac graft survival for >100 days
in 100% of wild-type and STAT4-/- mice. However, 14% of
CTLA4-Ig-treated STAT6-/- mice rejected their grafts
between 20 and 100 days. Moreover, of those animals followed past 100
days, 60% of the STAT6-/- mice rejected their grafts.
Splenocytes harvested on day 145 posttransplant from CTLA4-Ig-treated
rejecting STAT6-/- recipients were transfused into
syngeneic SCID mice transplanted with donor or third party cardiac
allografts. Both donor and third party grafts were rejected, indicating
that the initial graft loss may be due to an immunological rejection.
In contrast, when splenocytes from CTLA4-Ig-treated wild-type or
nonrejecting STAT6-/- mice were transferred into SCID
recipients, donor allografts were accepted, but third party hearts were
rejected. Thus, long-term prolongation of cardiac allograft survival by
CTLA4-Ig is STAT4-independent but, at least in part, STAT6-dependent.
These data suggest that the balance of type 1 and type 2 T lymphocyte
differentiation is not critical for acute rejection but influences the
robust tolerance induced by CD28/B7 blockade in this
model.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |